A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling

Abstract

Numerous colon cancer cases are resistant to chemotherapy based on oxaliplatin and suffer from relapse. A number of survival- and prognosis-related biomarkers have been identified based on database mining for patients who develop drug resistance, but the single individual gene biomarker cannot attain high specificity and sensitivity in prognosis prediction. This work was conducted aiming to establish a new gene signature using oxaliplatin resistance-related genes to predict the prognosis for colon cancer. To this end, we downloaded gene expression profile data of cell lines that are resistant and not resistant to oxaliplatin from the Gene Expression Omnibus (GEO) database. Altogether, 495 oxaliplatin resistance-related genes were searched by weighted gene co-expression network analysis (WGCNA) and differential expression analysis. As suggested by functional analysis, the above genes were mostly enriched into cell adhesion and immune processes. Besides, a signature was built based on four oxaliplatin resistance-related genes selected from the training set to predict the overall survival (OS) by stepwise regression and least absolute shrinkage and selection operator (LASSO) Cox analysis. Relative to the low risk score group, the high risk score group had dismal OS (P < 0.0001). Moreover, the area under the curve (AUC) value regarding the 5-year OS was 0.72, indicating that the risk score was accurate in the prediction of OS for colon cancer patients (AUC >0.7). Additionally, multivariate Cox regression suggested that the signature constructed based on four oxaliplatin resistance-related genes predicted the prognosis for colon cancer cases [hazard ratio (HR), 2.77; 95% CI, 2.03–3.78; P < 0.001]. Finally, external test sets were utilized to further validate the stability and accuracy of oxaliplatin resistance-related gene signature for prognosis of colon cancer patients. To sum up, this study establishes a signature based on four oxaliplatin resistance-related genes for predicting the survival of colon cancer patients, which sheds more light on the mechanisms of oxaliplatin resistance and helps identify colon cancer cases with a dismal prognostic outcome.

Cirsiliol regulates mitophagy in colon cancer cells via STAT3 signaling

“…CC is the leading cause of tumor-related death in many countries [20]. Currently, surgery combined with chemotherapy is the main treatment of colon cancer [21]. The current chemotherapies for colon cancer often offer limited help because cancer cells are relatively resistant to chemotherapy and promote tumor relapse and metastasis [22].…”

Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance

“…Wang, Ma, et al, 2020), irinotecan (Nielsen et al, 2017), and oxaliplatin (Q. Lin et al, 2021) in colorectal cancer; cisplatin (W.-C. Huang et al, 2019), carboplatin (X. Liu et al, 2019) and docetaxel (Sosa Iglesias et al, 2018) in lung cancer strongly suggests that the occurrence of chemoresistance seriously endangers the health and life of cancer patients.…”

“…Resistance to 5‐FU (N. Zhang et al, 2008), cisplatin (D. Huang et al, 2016), and docetaxel (Li et al, 2014) show a similar outcome in gastric cancer patients. Moreover, the resistance to 5‐FU (B. Wang, Ma, et al, 2020), irinotecan (Nielsen et al, 2017), and oxaliplatin (Q. Lin et al, 2021) in colorectal cancer; cisplatin (W.‐C. Huang et al, 2019), carboplatin (X. Liu et al, 2019) and docetaxel (Sosa Iglesias et al, 2018) in lung cancer strongly suggests that the occurrence of chemoresistance seriously endangers the health and life of cancer patients.…”

Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them

“…Resistance to 5-fluorouracil [13], cisplatin [14][15][16], docetaxel [17,18] and oxaliplatin [19] result in the same outcomes in gastric cancer patients. Moreover, the resistance to 5-fluorouracil [20], irinotecan [21], and oxaliplatin [22] in colorectal cancer, cisplatin [23,24], carboplatin [25,26], paclitaxel 23] and docetaxel [27,28] in lung, and gemcitabine [29], oxaliplatin [30], cisplatin [28,31] and doxorubicin [28] strongly indicate that the chemoresistance phenomenon intensively threatens the health and survival of cancer patients. Approximately 80-90% of mortality in cancer patients is directly or indirectly attributed to drug resistance [32].…”